Lifecore Biomedical, Inc. (LFCR) stock
LFCRNasdaqPharmaceutical PreparationsFiscal year ends May 25
$6.42+0.02 (+0.31%)
Close on Nov 13, 2026Market cap $243.02MP/E –Yield –
Lifecore Biomedical total assets
Total assets on the balance sheet at the end of each period.
Lifecore Biomedical's total assets was $228.30M at Sep 30, 2026. For fiscal 2025 it was $239.34M, down 5.8% from the year before. Over ten years it grew -3.6% a year on average. The highest annual figure on record is $519.09M in fiscal 2019.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | May 25, 2025 | $239.34M | -5.8% |
| FY2024 | May 26, 2024 | $253.96M | +0.2% |
| FY2023 | May 28, 2023 | $253.55M | -7.7% |
| FY2022 | May 29, 2022 | $274.70M | -45.3% |
| FY2021 | May 30, 2021 | $501.89M | +71.0% |
| FY2020 | May 31, 2020 | $293.50M | -43.5% |
| FY2019 | May 26, 2019 | $519.09M | +28.3% |
| FY2018 | May 27, 2018 | $404.70M | +12.9% |
| FY2017 | May 28, 2017 | $358.61M | +4.7% |
| FY2016 | May 29, 2016 | $342.65M | -1.1% |
| FY2015 | May 31, 2015 | $346.47M | +10.5% |
| FY2014 | May 25, 2014 | $313.62M | +7.8% |
| FY2013 | May 26, 2013 | $290.94M | +4.8% |
| FY2012 | May 27, 2012 | $277.69M | +34.6% |
| FY2011 | May 29, 2011 | $206.31M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2027CQ1 2026 | Sep 30, 2026 | $228.30M | -4.0% |
| Q2 FY2027CQ4 2025 | Jun 30, 2026 | $229.50M | -10.1% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $235.20M | -4.7% |
| Q4 FY2025CQ2 2025 | May 25, 2025 | $239.34M | -5.8% |
| Q3 FY2025CQ1 2025 | Feb 23, 2025 | $237.69M | -3.5% |
| Q2 FY2025CQ4 2024 | Nov 24, 2024 | $255.39M | +3.9% |
| Q1 FY2025CQ3 2024 | Aug 25, 2024 | $246.82M | +0.5% |
| Q4 FY2024CQ2 2024 | May 26, 2024 | $253.96M | +0.2% |
| Q3 FY2024CQ1 2024 | Feb 25, 2024 | $246.24M | +4.1% |
| Q2 FY2024CQ4 2023 | Nov 26, 2023 | $245.82M | -10.9% |
| Q1 FY2024CQ3 2023 | Aug 27, 2023 | $245.62M | -7.8% |
| Q4 FY2023CQ2 2023 | May 28, 2023 | $253.55M | -7.7% |
| Q3 FY2023CQ1 2023 | Feb 26, 2023 | $236.66M | -27.0% |
| Q2 FY2023CQ4 2022 | Nov 27, 2022 | $275.97M | -34.5% |
| Q1 FY2023CQ3 2022 | Aug 28, 2022 | $266.38M | -40.1% |
| Q4 FY2022CQ2 2022 | May 29, 2022 | $274.70M | -45.3% |
| Q3 FY2022CQ1 2022 | Feb 27, 2022 | $324.24M | -36.0% |
| Q2 FY2022CQ4 2021 | Nov 28, 2021 | $421.31M | -15.4% |
| Q1 FY2022CQ3 2021 | Aug 29, 2021 | $444.73M | -11.6% |
| Q4 FY2021CQ2 2021 | May 30, 2021 | $501.89M | +71.0% |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | $506.86M | -7.9% |
| Q2 FY2021CQ4 2020 | Nov 29, 2020 | $498.07M | -11.1% |
| Q1 FY2021CQ3 2020 | Aug 30, 2020 | $503.04M | -7.9% |
| Q4 FY2020CQ2 2020 | May 31, 2020 | $293.50M | -43.5% |
| Q3 FY2020CQ1 2020 | Feb 23, 2020 | $550.06M | +9.7% |
| Q2 FY2020CQ4 2019 | Nov 24, 2019 | $560.00M | +36.0% |
| Q1 FY2020CQ3 2019 | Aug 25, 2019 | $546.14M | +35.6% |
| Q4 FY2019CQ2 2019 | May 26, 2019 | $519.09M | +28.3% |
| Q3 FY2019CQ1 2019 | Feb 24, 2019 | $501.58M | +30.0% |
| Q2 FY2019CQ4 2018 | Nov 25, 2018 | $411.65M | +8.5% |
| Q1 FY2019CQ3 2018 | Aug 26, 2018 | $402.90M | +9.8% |
| Q4 FY2018CQ2 2018 | May 27, 2018 | $404.70M | +12.9% |
| Q3 FY2018CQ1 2018 | Feb 25, 2018 | $385.84M | +11.5% |
| Q2 FY2018CQ4 2017 | Nov 26, 2017 | $379.31M | +11.1% |
| Q1 FY2018CQ3 2017 | Aug 27, 2017 | $366.97M | +6.7% |
| Q4 FY2017CQ2 2017 | May 28, 2017 | $358.61M | +4.7% |
| Q3 FY2017CQ1 2017 | Feb 26, 2017 | $346.14M | – |
| Q2 FY2017CQ4 2016 | Nov 27, 2016 | $341.34M | – |
| Q1 FY2017CQ3 2016 | Aug 28, 2016 | $343.77M | – |
| Q4 FY2016CQ2 2016 | May 29, 2016 | $342.65M | – |
See a number that looks wrong?